Stem Cell Transplantation in Iran; 1991 until 2009


Hematology- Oncology and Stem Cell Transplantation Research Center related to Tehran University of Medical Sciences located in Shariati Hospital. These center activities have started in 1991 in order to help needful patients and augment new data to reach new aspects of therapeutic trials. Also it is one of the greatest Stem Cell Transplantation centers in world and is the second center in the world based on the transplanted Thalassemia patients. Since 1991, 2426 first Hematopoietic Stem Cell Transplantation (HSCT) has been performed in patients with different diseases. AcuteMyelogenous Leukemia (647 patients), Thalassemia Major (386 patients) and Acute Lymphoblastic Leukemia (335 patients) were the most common transplanted disorders, respectively. There were 1662 cases that have received allogeneic HSCT and 764 cases that have received autologous HSCT. Number of allogeneic ant autologous HSCT is increased during the time, but the allogeneic to autologous ratio remains constant.The first peripheral blood Hematopoietic Stem Cell Transplantation was performed in 1996 and since then, there was 1988 patients were done with this method. The donor types for 1662 allogeneic first HSCT were 1577 (94.9%) Human Leukocyte Antigen (HLA) matched-identical siblings, 44 (2.6%), HLA mismatched sibling/other relative, 16 (1%) syngeneic twins, 18 (1.1%) HLA matched other relative and 7 (0.4%) unrelated.  The first cord blood Hematopoietic Stem Cell Transplantation was performed in 1998 and since then there was 16 patients that have obtained cord blood transplantations. Recently, new methods have been used like Donor Lymphocyte Infusion (DLI) and Cellular Therapy. There were 147 patients with Cellular Therapy for post MI, Cirrhosis, Thalassemia major, Multiple Sclerosis, Head of Femour Necrosis and GvHD treatment.

Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175-181.

Appelbaum FR. Hematopoietic Cell Transplantation. In: Kasper DL, Braunward E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s principles of internal medicine. 16th ed. New York, NY: McGraw‐Hill; 2005. p. 668-673.

Ghavamzadeh A, Jahani M, Baybordi I. Bone Marrow transplantation in Iran. Bone Marrow Transplant. 1994;13(6):743-744.

Ghavamzadeh A, Alimoghaddam K, Jahani M, et al. Hematopoietic stem cell transplantation in Iran: 1991 to 2008. Hematol Oncol Stem Cell Ther. 2008;1(4):231-8.

Ghavamzadeh A, Alimoghaddam K, Jahani M, et al. Stem Cell Transplantation: Iranian Experience. Arch Iranian Med. 2009;12(1):69-72.

Ghavamzadeh A, Nasseri P, Eshraghian MR, et al. Prognostic factors in bone marrow transplantation for beta thalassemia major: experiences from Iran. Bone Marrow Transplant. 1998;22(12):1167-1169.

Iravani M, Evazi MR, Mousavi SA, et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients. Bone Marrow Transplant. 2007;40(2):105- 110.

Aljurf MD, Zaidi SZ, El Solh H, et al. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant. 2009;43(1):1-12.

Gratwohl A, Passweg J, Baldomero H, et al. For the accrediation committee of the European Group for Blood and Marrow Transplantation (EBMT). Economic, health care systems and utilization of hematopoietic stem cell transplants in Europe. Br J Haematol. 2002;117:451-468.

Collins RH Jr. Management of relapse after Allogeneic transplantation. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas' Hematopoietic Cell Transplantation. 3rd ed. Malden, MA: Blackwell Science; 2004. p. 1150-1163.

Gratwohl A, Baldomero H, Schwendener A, et al. Predictability of hematopoietic stem cell transplantation rates. Haematologica. 2007;92(12):1679-1686.

Iravani M., Mousavi S.A., Gholibeikian S., et al. Cyclosporine disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation. Bone Marrow Transplant. 2005;35:1095- 1099.

Gratwohl A, Baldomero H, Frauendorfer K, et al. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products. Bone Marrow Transplant. 2008;41(8):687-705.

Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002 Oct 1;100(7):2374-2386.

IssueVol 3, No 1 (2009) QRcode
Allogeneic Autologous Stem Cell Transplantation Thalassemia Hematologic Malignancies

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA- o- allah, Iravani M, Bahar B, Khodabandeh A, Khatami F, Jalali A. Stem Cell Transplantation in Iran; 1991 until 2009. Int J Hematol Oncol Stem Cell Res. 1;3(1):27-33.